Clinical Trials Browser

Active not recruiting × Neoadjuvant Therapy × Head & Neck × Clear all

NCT05724329 2024-09-19

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck